Big pharma is discovering that one of most important factors to accelerate the pace of drug development is to reduce the physical distance between internal R&D labs and external partners. Consequently, most have set up R&D hubs close to ground zero of drug discovery – in major U.S. cities with important academic and medical centers that boast a highly skilled work force and access to risk capital.